Bone mass loss in chronic heart failure is associated with secondary hyperparathyroidism and has prognostic significance

European Journal of Heart Failure

Volumn 14, Issue 3, 2012, Pages 326-332

  Terrovitis, John ^a   Zotos, Panagiotis ^a   Kaldara, Elissavet ^a   Diakos, Nikolaos ^a   Tseliou, Eleni ^a   Vakrou, Stella ^d   Kapelios, Chris ^a   Chalazonitis, Athanasios ^b   Nanas, Serafeim ^a   Toumanidis, Savas ^a   Kontoyannis, Dimitrios ^c   Karga, Eleni ^a   Nanas, John ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

^c ALEXANDRA HOSPITAL   (Greece)

^d Department of Radiology ^*

Author keywords

Bone mineral density; Heart failure; Hyperparathyroidism; Mortality; Osteoporosis; Vitamin D

Indexed keywords

INOTROPIC AGENT; PARATHYROID HORMONE; VITAMIN D;

ADIPOSE TISSUE; ADULT; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DISEASE SEVERITY; FOLLOW UP; HEART FAILURE; HEART INDEX; HUMAN; LEAN BODY WEIGHT; LEFT VENTRICULAR ASSIST DEVICE; LUNG WEDGE PRESSURE; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROGNOSIS; SECONDARY HYPERPARATHYROIDISM;

ABSORPTIOMETRY, PHOTON; BONE DENSITY; CARDIOMYOPATHIES; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DISEASE PROGRESSION; HEALTH STATUS INDICATORS; HEART FAILURE, DIASTOLIC; HEART-ASSIST DEVICES; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; OSTEOPOROSIS; OXYGEN CONSUMPTION; PARATHYROID HORMONE; PROGNOSIS; RISK ASSESSMENT; STATISTICS AS TOPIC; STATISTICS, NONPARAMETRIC; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT; VITAMIN D;

EID: 84857545238     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfs002     Document Type: Article

References (32)

1. Aronow WS. Heart disease and aging. Med Clin North Am 2006;90:849-862.
2. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P. Heart disease stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:85-151.
3. Tendera M. Epidemiology, treatment, and guidelines for the treatment of heart failure in Europe. Eur Heart J 2005;7(Suppl):J5-J9.
4. Reginster JY, Burlet NY. Osteoporosis: a still increasing prevalence. Bone 2006;38:S4-S9.
5. Van Diepen S, Majumdar SR, Bakal JA, McAlister FA, Ezekowitz JA. Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16 294 patients. Circulation 2008;118:1946-1952.
6. Keen RW. Burden of osteoporosis and fractures. Curr Osteoporos Rep 2003;1:66-70.
7. Carbone L, Buzková P, Fink HA, Lee JS, Chen Z, Ahmed A, Parashar S, Robbins JR. Hip fractures and heart failure: findings from the Cardiovascular Health Study. Eur Heart J 2010;31:77-84.
8. Gerber Y, Meton LJ 3rd, Weston SA, Roger VL. Osteoporotic fractures and heart failure in the community. Am J Med 2011:124:418-425.
9. Sugimoto T, Tanigawa T, Onishi K, Fujimoto N, Matsuda A, Nakamori S, Matsuoka K, Nakamura T, Koji T, Ito M. Serum intact parathyroid hormone levels predict hospitalisation for heart failure. Heart 2009;95:395-398.
10. Hagström E, Ingelsson E, Sundström J, Hellman P, Larsson T, Berglund L, Melhus H, Held C, Michaëlsson K, Lind L, Ärnlöv J. Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail 2010;12:1186-1192.
11. Liu LCY, Voors AA, van Veldhuisen DJ, van der Veer E, Belonje AM, Szymanski MK, Silljé HHW, van Gilst WH, Jaarsma T, de Boer RA. Vitamin D status and outcomes in heart failure patients. Eur J Heart Fail 2011;13:619-625.
12. Jankowska EA, Jakubaszko J, Cwynar A, Majda J, Ponikowska B, Kustrzycka-Kratochwil D, Reczuch K, Borodulin-Nadzieja L, Banasiak W, Poole-Wilson PA, Ponikowski P. Bone mineral status and bone loss over time in men with chronic systolic heart failure and their clinical and hormonal determinants. Eur J Heart Fail 2009;11:28-38.
13. Anker SD, Clark AL, Teixeira MM, Hellewell PG, Coats AJ. Loss of bone mineral in patients with cachexia due to chronic heart failure. Am J Cardiol 1999;83:612-615.
14. Muchmore JS, Cooper DK, Ye Y, Schlegel V, Pribil A, Zuhdi N. Prevention of loss of vertebral bone density in heart transplant patients. J Heart Lung Transplant 1992;11:959-963.
15. Shane E, Mancini D, Aaronson K, Silverberg SJ, Seibel MJ, Addesso V, McMahon DJ. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 1997;103:197-207.
16. Frost RJA, Sonne C, Wehr U, Stempfle HU. Effects of calcium supplementation on bone loss and fractures in congestive heart failure. Eur J Endocrinol 2007;156:309-314.
17. Raza SH, Law P, Farooqui N, Carbone LD. Atraumatic fractures in heart failure. Am J Med Sci 2009;338:45-47.
18. Kenny AM, Boxer R, Walsh S, Hager WD, Raisz LG. Femoral bone mineral density in patients with heart failure. Osteoporos Int 2006;17:1420-1427.
19. Adams JE. Single and dual energy X-ray absorptiometry. Eur Radiol 1997;7(Suppl. 2): S20-S31.
20. Kellie SE. Measurement of bone density with dual energy X-ray absorptiometry (DEXA). JAMA 1992;267:286-294.
21. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-1141.
22. Lewieckie EM, Watts NB, McClung MR, Petak SM, Backrach LK, Shepherd JA, Downs RW. Official positions of the International Society for Clinical Densitometry. J Clin Endocrinol Metab 2004;89:3651-3655.
23. Albouaini K, Egred M, Alahmar A, Wright DJ. Cardiopulmonary exercise testing and its application. Heart 2007;93:1285-1292.
24. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001;22:477-501.
25. Schierbeck LL, Jensen TS, Bang U, Jensen G, Køber L, Jensen JEB. Parathyroid hormone and vitamin D-markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail 2011;13:626-632.
26. Ezekowitz JA. A new pathway? Failure, fragility and fractures. Eur Heart J 2010;31:9-11.
27. Tastan I, Schreckenberg R, Mufti S, Abdallah Y, Piper HM, Schlüter KD. Parathyroid hormone improves contractile performance of adult rat ventricular cardiomyocytes at low concentrations in a non-acute way. Cardiovasc Res 2009;82:77-83.
28. Clemens TL, Cormier S, Eichinger A, Endlich K, Fiaschi-Taesch N, Fischer E, Friedman PA, Karaplis AC, Massfelder T, Rossert J, Schlüter KD, Silve C, Stewart AF, Takane K, Helwig JJ. Parathyroid hormone-related protein and its receptors: nuclear functions and roles in the renal and cardiovascular systems, the placental trophoblasts and the pancreatic islets. Br J Pharmacol 2001;134:1113-1135.
29. Lyons KJ, Majumbar SR, Ezekowitz JA. The unrecognized burden of osteoporosis-related vertebral fractures in patients with heart failure. Circ Heart Fail 2011;4:419-424.
30. Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD, Alexopoulos G, Ktenas V, Rapti AC, Tsagalou EP, Nanas JN. Hormonal profile in patients with congestive heart failure. Int J Cardiol 2003;87:179-183.
31. Dings C, Parameswaran V, Udayan R, Burgess J, Jones G. Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab 2008;93:1952-1958.
32. Lee AH, Mull RL, Keenan GF, Callegari PE, Dalinka MK, Eisen HJ, Mancini DM, Di Sesa VJ, Attie MF. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med 1994;96:35-41.